Document is current
Any future updates will be listed below
-
Authors
Smalbrugge, David
Walsteijn, Tim https://orcid.org/0009-0004-6314-1203
de Feijter, Jeantine
Suelmann, Britt
Kearney, Mairead
Benedict, Agnes
Kapetanakis, Venediktos
van Beekhuizen, Sophie
-
Funding
Funding for this research was provided by:
Merck Healthcare KGaA
- License Information
-
More Information
Article History
Received: 13 November 2024
Accepted: 16 April 2025
First Online: 17 May 2025
Declarations
:
: David Smalbrugge and Sophie van Beekhuizen are full-time employees of Cytel. Tim Walsteijn is a full-time employee of Merck B.V., Schiphol-Rijk, Netherlands, an affiliate of Merck KGaA. Mairead Kearney is a full-time employee of Merck Healthcare KGaA, Darmstadt, Germany. Agnes Benedict and Venediktos Kapetanakis are full-time employees of Evidera. JdF has participated in advisory boards for Janssen. Britt Suelmann has participated in medical advisory boards for MSD, Merck, BMS, IPSEN, Janssen, AstraZeneca, Pfizer and has been a study sponsor of Pfizer, Janssen, Astellas and AstraZeneca.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
